Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + nanoparticle albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of pembrolizumab (an anti-PD-1 monoclonal antibody) and nanoparticle albumin-bound paclitaxel (a taxane chemotherapy agent). This combination is used primarily for the treatment of metastatic squamous non-small cell lung cancer (NSCLC), often administered with carboplatin as part of a first-line treatment regimen. The combination works by both enhancing the immune system's ability to detect and fight cancer cells (pembrolizumab) and by disrupting cancer cell division (paclitaxel).
- Brand names
- AbraxaneKeytruda
- Other names
- pembrolizumab + nab-paclitaxel
02
Targets
MicrotubulePDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + nanoparticle albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + nanoparticle albumin-bound paclitaxel.